OMRIX BIOPHARMACEUTICALS
De berekende faillissementskans van OMRIX BIOPHARMACEUTICALS over 12 maanden bedraagt 0,4% (zeer laag). Het bedrijf is actief sinds 1995 en het Belgisch Staatsblad bevat geen insolventie- of waarschuwingssignalen. Er zijn geen verwerkte jaarrekeningcijfers beschikbaar; deze conclusie steunt uitsluitend op register- en Staatsbladgegevens.
| Actief | 30 jaar |
| Vestigingen | 1 |
| Publicaties | 14 |
Statistische inschatting op basis van openbare bronnen — geen kredietadvies of vaststelling. Hoe berekenen we dit?
| Boekjaar | Type | Neerlegging | Referentie |
|---|---|---|---|
| 31-12-2024 | volledig | 11-07-2025 | 2025-00267641 |
| 31-12-2023 | volledig | 05-07-2024 | 2024-00236558 |
| 31-12-2022 | volledig | 10-07-2023 | 2023-00220703 |
| 31-12-2021 | volledig | 27-06-2022 | 2022-20107626 |
| 31-12-2020 | volledig | 07-09-2021 | 2021-66800248 |
| 31-12-2019 | volledig | 09-07-2021 | 2021-34900588 |
| 31-12-2018 | volledig | 28-06-2019 | 2019-23900579 |
| 31-12-2017 | volledig | 02-07-2018 | 2018-26500418 |
| 31-12-2016 | volledig | 08-08-2017 | 2017-42300184 |
| 31-12-2015 | volledig | 22-08-2016 | 2016-47200184 |
| NACE primair | Groothandel(46460) |
| Rechtsvorm | NV(014) |
| Oprichtingsdatum | 31-08-1995 |
| Status | Actief |
| Postcode | 1831 |
Percelen gekoppeld aan dit bedrijf via zijn adressen in de KBO (zetel, vestigingen, bijkantoren), gekruist met het kadastraal percelenplan. Dit toont waar het bedrijf actief is — geen eigendomsregister.
| Perceel (capakey) | Regio | Oppervlakte | Gebouwen | Hoogte / verd. |
|---|---|---|---|---|
| 23015B0291/02B000 | Vlaanderen | 1,1 ha | 1 · 2.579 m² | 20,4 m · 6 verd. |
Eén tijdlijn van alles wat er met dit bedrijf is gebeurd — publicaties, insolventie- en levensloopgebeurtenissen, administratieve wijzigingen en neergelegde jaarrekeningen.
30-07-2024 2 bestuurders benoemd
- PWC Bedrijfsrevisoren BV — Commissaris
- Roel Boons — Vertegenwoordiger commissaris
Technische details
{
"events": [
{
"kind": "director_in",
"role": "commissaris",
"person": {
"rrn": null,
"name": "PWC Bedrijfsrevisoren BV",
"address": null,
"birth_date": null
}
},
{
"kind": "director_in",
"role": "vertegenwoordiger commissaris",
"person": {
"rrn": null,
"name": "Roel Boons",
"address": null,
"birth_date": null
}
}
],
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"subject_company": {
"kbo": "0455.883.073",
"name_full": "OMRIX BIOPHARMACEUTICALS"
}
}06-09-2023 1 bestuurder benoemd, 2 ontslagnemend
- Elena GIRONI — Bestuurder
- Beverly PHARAOH — Bestuurder
- Sylvie BIANCHI — Bestuurder
Technische details
{
"events": [
{
"kind": "director_out",
"role": "bestuurder",
"person": {
"rrn": null,
"name": "Beverly PHARAOH",
"address": null,
"birth_date": null
}
},
{
"kind": "director_out",
"role": "bestuurder",
"person": {
"rrn": null,
"name": "Sylvie BIANCHI",
"address": null,
"birth_date": null
}
},
{
"kind": "director_in",
"role": "bestuurder",
"person": {
"rrn": null,
"name": "Elena GIRONI",
"address": null,
"birth_date": null
}
}
],
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"subject_company": {
"kbo": "0455.883.073",
"name_full": "OMRIX BIOPHARMACEUTICALS"
}
}19-07-2023 1 bestuurder benoemd, 1 ontslagnemend
- Sylvie BIANCHI — Bestuurder
- Beverly PHARAOH — Bestuurder
Technische details
{
"events": [
{
"kind": "director_out",
"role": "bestuurder",
"person": {
"rrn": null,
"name": "Beverly PHARAOH",
"address": null,
"birth_date": null
}
},
{
"kind": "director_in",
"role": "bestuurder",
"person": {
"rrn": null,
"name": "Sylvie BIANCHI",
"address": null,
"birth_date": null
}
}
],
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"subject_company": {
"kbo": "0455.883.073",
"name_full": "OMRIX BIOPHARMACEUTICALS"
}
}22-07-2022 Wijziging in het bestuur
Technische details
{
"events": [],
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"subject_company": {
"kbo": "0455.883.073",
"name_full": "OMRIX BIOPHARMACEUTICALS"
}
}20-09-2021 Pricewaterhousecoopers BV benoemd tot commissaris
- Pricewaterhousecoopers BV — Commissaris
Technische details
{
"events": [
{
"kind": "director_in",
"role": "commissaris",
"person": {
"rrn": null,
"name": "Pricewaterhousecoopers BV",
"address": null,
"birth_date": null
}
}
],
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"subject_company": {
"kbo": "0455.883.073",
"name_full": "OMRIX BIOPHARMACEUTICALS"
}
}06-03-2020 8 bestuurders benoemd
- Hilde Claes — Lasthebber
- An de Schutter — Gemachtigde
- Heidi Moyson — Lasthebber
- Inge Gabriëls — Lasthebber
- Sophie Totté — Lasthebber
- Audrey Rottier — Lasthebber
- Eva Veraghtert — Lasthebber
- Leen Van De Wiel — Gemachtigde
Technische details
{
"events": [
{
"kind": "director_in",
"role": "Lasthebber",
"person": {
"rrn": null,
"name": "Hilde Claes",
"address": null,
"birth_date": null
}
},
{
"kind": "director_in",
"role": "Gemachtigde",
"person": {
"rrn": null,
"name": "An de Schutter",
"address": null,
"birth_date": null
}
},
{
"kind": "director_in",
"role": "Lasthebber",
"person": {
"rrn": null,
"name": "Heidi Moyson",
"address": null,
"birth_date": null
}
},
{
"kind": "director_in",
"role": "Lasthebber",
"person": {
"rrn": null,
"name": "Inge Gabri\u00EBls",
"address": null,
"birth_date": null
}
},
{
"kind": "director_in",
"role": "Lasthebber",
"person": {
"rrn": null,
"name": "Sophie Tott\u00E9",
"address": null,
"birth_date": null
}
},
{
"kind": "director_in",
"role": "Lasthebber",
"person": {
"rrn": null,
"name": "Audrey Rottier",
"address": null,
"birth_date": null
}
},
{
"kind": "director_in",
"role": "Lasthebber",
"person": {
"rrn": null,
"name": "Eva Veraghtert",
"address": null,
"birth_date": null
}
},
{
"kind": "director_in",
"role": "Gemachtigde",
"person": {
"rrn": null,
"name": "Leen Van De Wiel",
"address": null,
"birth_date": null
}
}
],
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"subject_company": {
"kbo": "0455.883.073",
"name_full": "Omrix Biopharmaceuticals"
}
}30-12-2019 Statutenwijziging
Technische details
{
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"name_change": {
"new": "",
"old": "",
"changed": false
},
"seat_change": {
"changed": false
},
"object_change": {
"changed": false
},
"subject_company": {
"kbo": "0455.883.073",
"name_full": "OMRIX BIOPHARMACEUTICALS"
},
"legal_form_change": {
"new": "naamloze vennootschap",
"old": "naamloze vennootschap",
"changed": false
}
}26-09-2019 1 bestuurder benoemd, 1 ontslagnemend
- Peter D'hondt — Vertegenwoordiger van de commissaris
- Bart Van Gompel — Vertegenwoordiger van de commissaris
Technische details
{
"events": [
{
"kind": "director_out",
"role": "vertegenwoordiger van de commissaris",
"person": {
"rrn": null,
"name": "Bart Van Gompel",
"address": null,
"birth_date": null
}
},
{
"kind": "director_in",
"role": "vertegenwoordiger van de commissaris",
"person": {
"rrn": null,
"name": "Peter D\u0027hondt",
"address": null,
"birth_date": null
}
}
],
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"subject_company": {
"kbo": "0455.883.073",
"name_full": "Omrix Biopharmaceuticals"
}
}18-07-2018 1 bestuurder benoemd, 1 ontslagnemend
- PricewaterhouseCoopers Bedrijfsrevisoren BV CVBA — Auditor
- PricewaterhouseCoopers Bedrijfsrevisoren BV CVBA — Auditor
Technische details
{
"events": [
{
"kind": "director_in",
"role": "auditor",
"person": {
"rrn": null,
"name": "PricewaterhouseCoopers Bedrijfsrevisoren BV CVBA",
"address": null,
"birth_date": null
}
},
{
"kind": "director_out",
"role": "auditor",
"person": {
"rrn": null,
"name": "PricewaterhouseCoopers Bedrijfsrevisoren BV CVBA",
"address": null,
"birth_date": null
}
}
],
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"subject_company": {
"kbo": "0455.883.073",
"name_full": "Omrix Biopharmaceuticals"
}
}11-07-2017 2 bestuurders benoemd, 1 ontslagnemend
- Wim Adriaenssens — Bestuurder
- Beverly Pharaoh — Bestuurder
- Raf Uyttenbroeck — Bestuurder
Technische details
{
"events": [
{
"kind": "director_out",
"role": "bestuurder",
"person": {
"rrn": null,
"name": "Raf Uyttenbroeck",
"address": null,
"birth_date": null
}
},
{
"kind": "director_in",
"role": "bestuurder",
"person": {
"rrn": null,
"name": "Wim Adriaenssens",
"address": null,
"birth_date": null
}
},
{
"kind": "director_in",
"role": "bestuurder",
"person": {
"rrn": null,
"name": "Beverly Pharaoh",
"address": null,
"birth_date": null
}
}
],
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"subject_company": {
"kbo": "0455.883.073",
"name_full": "Omrix Biopharmaceuticals"
}
}24-09-2015 2 bestuurders benoemd
- PricewaterhouseCoopers Bedrijfsrevisoren BV CVBA — Commissaris
- Bart Van Gompel — Bedrijfsrevisor
Technische details
{
"events": [
{
"kind": "director_in",
"role": "commissaris",
"person": {
"rrn": null,
"name": "PricewaterhouseCoopers Bedrijfsrevisoren BV CVBA",
"address": null,
"birth_date": null
}
},
{
"kind": "director_in",
"role": "bedrijfsrevisor",
"person": {
"rrn": null,
"name": "Bart Van Gompel",
"address": null,
"birth_date": null
}
}
],
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"subject_company": {
"kbo": "0455.883.073",
"name_full": "Omrix Biopharmaceuticals"
}
}02-02-2011 Statutenwijziging
Technische details
{
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"name_change": {
"new": "",
"old": "",
"changed": false
},
"seat_change": {
"changed": false
},
"object_change": {
"changed": false
},
"subject_company": {
"kbo": "0455.883.073",
"name_full": "OMRIX BIOPHARMACEUTICALS"
},
"legal_form_change": {
"new": "naamloze vennootschap",
"old": "naamloze vennootschap",
"changed": false
}
}02-02-2011 Kapitaalvermindering van €13.352.787,04 tot €61.500
- €13.414.287,04 → €61.500
- Inbreng in geld · Apport en numéraire
Technische details
{
"events": [
{
"kind": "capital_decrease",
"after_eur": 61500.0,
"delta_eur": -13352787.04,
"before_eur": 13414287.04,
"contribution_type": "geld"
}
],
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"subject_company": {
"kbo": "0455.883.073",
"name_full": "OMRIX BIOPHARMACEUTICALS"
}
}30-10-2009 4 bestuurders benoemd
- Marci Blazer — Bestuurder
- Chery Foytlin — Bestuurder
- James J. Bergin — Bestuurder
- Elizabeth Forminard — Bestuurder
Technische details
{
"events": [
{
"kind": "director_in",
"role": "administrateur",
"person": {
"rrn": null,
"name": "Marci Blazer",
"address": null,
"birth_date": null
}
},
{
"kind": "director_in",
"role": "administrateur",
"person": {
"rrn": null,
"name": "Chery Foytlin",
"address": null,
"birth_date": null
}
},
{
"kind": "director_in",
"role": "administrateur",
"person": {
"rrn": null,
"name": "James J. Bergin",
"address": null,
"birth_date": null
}
},
{
"kind": "director_in",
"role": "administrateur",
"person": {
"rrn": null,
"name": "Elizabeth Forminard",
"address": null,
"birth_date": null
}
}
],
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"subject_company": {
"kbo": "0455.883.073",
"name_full": "OMRIX BIOPHARMACEUTICALS"
}
}Genereer een gestructureerde, feitelijke nota op basis van alle signalen in dit dossier: risico, financiële gezondheid, eigendomsstructuur, mandaten en sectorvergelijking.
| Officiële naamNL | OMRIX BIOPHARMACEUTICALS |